Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR: A Prospective, Single-arm, Open-label Phase II Trial.
Blankenstein SA, Rohaan MW, Klop WMC, van der Hiel B, van de Wiel BA, Lahaye MJ, Adriaansz S, Sikorska K, van Tinteren H, Sari A, Grijpink-Ongering LG, van Houdt WJ, Wouters MWJM, Blank CU, Wilgenhof S, van Thienen JV, van Akkooi ACJ, Haanen JBAG.
Blankenstein SA, et al. Among authors: wouters mwjm.
Ann Surg. 2021 Aug 1;274(2):383-389. doi: 10.1097/SLA.0000000000004893.
Ann Surg. 2021.
PMID: 33843797
Clinical Trial.